Striking a balance between safety and efficacy: Experience with the SSRI sertraline

Daniel Casey

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Depression is a widespread and serious disorder inflicting an immeasurable toll on the lives of millions of people and affecting their families and colleagues. It is the cause of countless suicides especially in those whose illness has not been detected or given appropriate care. Until recently, effective pharmacotherapeutic management of depression was hampered by the troublesome side effects associated with traditional methods of treatment. In an attempt to circumvent these adverse effects, many anti-depressants were prescribed at less than therapeutic doses, resulting in a high probability of inadequate treatment, relapse, or recurrence. The development of the selective serotonin reuptake inhibitors (SSRIs) was guided by the need for an antidepressant that provided both safe and effective therapeutic benefit. Sertraline's potent and highly selective inhibition of serotonin accounts both for its efficacy in a broad spectrum of depression and for its high tolerability and ease of use. Its safety and tolerability have been demonstrated in acute and maintenance phases of treatment and establishes that sertraline provides a viable clinical alternative for acute and long-term care of depressed patients.

Original languageEnglish (US)
Pages (from-to)5-12
Number of pages8
JournalInternational Clinical Psychopharmacology
Volume9
StatePublished - 1994

Fingerprint

Sertraline
Serotonin Uptake Inhibitors
Safety
Depression
Therapeutics
Recurrence
Long-Term Care
Suicide
Antidepressive Agents
Serotonin
Maintenance

Keywords

  • Depression
  • Selective serotonin reuptake inhibitors
  • SSRIs

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Striking a balance between safety and efficacy : Experience with the SSRI sertraline. / Casey, Daniel.

In: International Clinical Psychopharmacology, Vol. 9, 1994, p. 5-12.

Research output: Contribution to journalArticle

@article{fa86648408a7481685c4446e1270116c,
title = "Striking a balance between safety and efficacy: Experience with the SSRI sertraline",
abstract = "Depression is a widespread and serious disorder inflicting an immeasurable toll on the lives of millions of people and affecting their families and colleagues. It is the cause of countless suicides especially in those whose illness has not been detected or given appropriate care. Until recently, effective pharmacotherapeutic management of depression was hampered by the troublesome side effects associated with traditional methods of treatment. In an attempt to circumvent these adverse effects, many anti-depressants were prescribed at less than therapeutic doses, resulting in a high probability of inadequate treatment, relapse, or recurrence. The development of the selective serotonin reuptake inhibitors (SSRIs) was guided by the need for an antidepressant that provided both safe and effective therapeutic benefit. Sertraline's potent and highly selective inhibition of serotonin accounts both for its efficacy in a broad spectrum of depression and for its high tolerability and ease of use. Its safety and tolerability have been demonstrated in acute and maintenance phases of treatment and establishes that sertraline provides a viable clinical alternative for acute and long-term care of depressed patients.",
keywords = "Depression, Selective serotonin reuptake inhibitors, SSRIs",
author = "Daniel Casey",
year = "1994",
language = "English (US)",
volume = "9",
pages = "5--12",
journal = "International Clinical Psychopharmacology",
issn = "0268-1315",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Striking a balance between safety and efficacy

T2 - Experience with the SSRI sertraline

AU - Casey, Daniel

PY - 1994

Y1 - 1994

N2 - Depression is a widespread and serious disorder inflicting an immeasurable toll on the lives of millions of people and affecting their families and colleagues. It is the cause of countless suicides especially in those whose illness has not been detected or given appropriate care. Until recently, effective pharmacotherapeutic management of depression was hampered by the troublesome side effects associated with traditional methods of treatment. In an attempt to circumvent these adverse effects, many anti-depressants were prescribed at less than therapeutic doses, resulting in a high probability of inadequate treatment, relapse, or recurrence. The development of the selective serotonin reuptake inhibitors (SSRIs) was guided by the need for an antidepressant that provided both safe and effective therapeutic benefit. Sertraline's potent and highly selective inhibition of serotonin accounts both for its efficacy in a broad spectrum of depression and for its high tolerability and ease of use. Its safety and tolerability have been demonstrated in acute and maintenance phases of treatment and establishes that sertraline provides a viable clinical alternative for acute and long-term care of depressed patients.

AB - Depression is a widespread and serious disorder inflicting an immeasurable toll on the lives of millions of people and affecting their families and colleagues. It is the cause of countless suicides especially in those whose illness has not been detected or given appropriate care. Until recently, effective pharmacotherapeutic management of depression was hampered by the troublesome side effects associated with traditional methods of treatment. In an attempt to circumvent these adverse effects, many anti-depressants were prescribed at less than therapeutic doses, resulting in a high probability of inadequate treatment, relapse, or recurrence. The development of the selective serotonin reuptake inhibitors (SSRIs) was guided by the need for an antidepressant that provided both safe and effective therapeutic benefit. Sertraline's potent and highly selective inhibition of serotonin accounts both for its efficacy in a broad spectrum of depression and for its high tolerability and ease of use. Its safety and tolerability have been demonstrated in acute and maintenance phases of treatment and establishes that sertraline provides a viable clinical alternative for acute and long-term care of depressed patients.

KW - Depression

KW - Selective serotonin reuptake inhibitors

KW - SSRIs

UR - http://www.scopus.com/inward/record.url?scp=0028300536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028300536&partnerID=8YFLogxK

M3 - Article

C2 - 7963450

AN - SCOPUS:0028300536

VL - 9

SP - 5

EP - 12

JO - International Clinical Psychopharmacology

JF - International Clinical Psychopharmacology

SN - 0268-1315

ER -